In preclinical animal models, CXCR2 antagonism or dual antagonism of CXCR2 and CXCR1 (CXCR1: a CXCL8 binding chemokine receptor highly expressed on neutrophils) has emerged as a promising complementary therapy potentiating cancer treatments by immune checkpoint blockade and antitumor T cell transfer [250,455,456,457,458,459]. This evidence concerns the gene CXCR2 and cancer.